Checkpoint.

In case you’re not convinced, another retrospective study, this one looking at 203 patients receiving radiosurgery for 1388 melanoma brain metastases across 11 international institutions, indicates no additional risk of symptomatic radionecrosis when immune checkpoint inhibitors are used concurrently (9.4%) versus at a different time (8.2%). This is in line with an analogous investigation of renal cell carcinoma brain mets. | Lehrer, Neurosurg 2022